KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Operating Leases: 2018-2024

Historic Operating Leases for Teva Pharmaceutical Industries (TEVA) over the last 7 years, with Dec 2024 value amounting to $296.0 million.

  • Teva Pharmaceutical Industries' Operating Leases fell 4.07% to $283.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $283.0 million, marking a year-over-year decrease of 4.07%. This contributed to the annual value of $296.0 million for FY2024, which is 29.02% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Operating Leases of $296.0 million as of FY2024, which was down 29.02% from $417.0 million recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Operating Leases registered a high of $595.0 million during FY2020, and its lowest value of $296.0 million during FY2024.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Operating Leases value was $417.0 million (recorded in 2023), while the average stood at $385.0 million.
  • Its Operating Leases has fluctuated over the past 5 years, first climbed by 7.59% in 2020, then declined by 29.02% in 2024.
  • Teva Pharmaceutical Industries' Operating Leases (Yearly) stood at $595.0 million in 2020, then decreased by 11.76% to $525.0 million in 2021, then declined by 15.81% to $442.0 million in 2022, then dropped by 5.66% to $417.0 million in 2023, then declined by 29.02% to $296.0 million in 2024.